论文信息 - A Clinical Study of Bradilan (Tetranicotinoylfructose) in Diabetic Patients with Peripheral Vascular Disease

A Clinical Study of Bradilan (Tetranicotinoylfructose) in Diabetic Patients with Peripheral Vascular Disease

Nineteen diabetic patients with peripheral vascular disease treated with Bradilan (tetranicotinoylfructose) tablets showed cure or improvement in 14 cases with no adverse effect on their diabetic control. It must therefore be considered a useful drug in the treatment of such diabetic patients with peripheral vascular problems.

C. Boroda

[1] P. Martín,et al. A Plethysmographic Study of the Effect of Tetranicotinoylfructose (Bradilan) On Digital Blood Flow in Primary and Secondary Raynaud's Phenomenon , 1974, Angiology.

[2] A. Kissebah,et al. The Mechanism of Action of Clofibrate and Tetranicotinoylfructose (Bradilan) on the Kinetics of Plasma Free Fatty Acid and Triglyceride Transport in Type IV und Type V Hypertriglyceridaemia , 1974, European journal of clinical investigation.

[3] F. Donnan. A Double-Blind Trial of Bradilan (Tetranicotinoylfructose) in Perniosis in General Practice , 1974 .

[4] T. Judge,et al. The action of tetranicotinoylfructose in peripheral vascular disease. , 1973, Practitioner.

[5] D. Newell,et al. Tetranicotinoylfructose in disorders of digital blood flow. , 1971, The Practitioner.

[6] G. Molnar,et al. THE EFFECT OF NICOTINIC ACID IN DIABETES MELLITUS. , 1964, Metabolism: clinical and experimental.

[7] Harvey Gurian,et al. THE EFFECT OF LARGE DOSES OF NICOTINIC ACID ON CIRCULATING LIPIDS AND CARBOHYDRATE TOLERANCE , 1959, The American journal of the medical sciences.